NK Cell Therapy in Osaka: Working With Your Home Oncologist

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

Many people who look into NK cell therapy in Japan are already receiving cancer care somewhere else. They may live in another country, in another part of Japan, or simply be treated at a hospital far from Osaka. In that situation, the practical question is often not only whether to consider the therapy, but how to keep every doctor involved in your care informed. This article explains how to approach that conversation in a calm, organized way before a consultation at Grand Green Osaka Umekita Clinic or any other clinic.

NK cell therapy is a cancer immune cell therapy. It is provided in Japan as a self-pay (non-insured) treatment, and its suitability, expected benefit and risks must be confirmed through a medical consultation. Nothing here is a promise of results, and it is not a replacement for standard cancer treatment.

The short answer: treat it as an addition to your care team, not a separate track

NK cell therapy, as described by the clinic, uses your own NK cells, which are collected by a standard blood draw, activated and expanded outside the body, and then returned by intravenous infusion. It is described as something that can be considered alongside surgery, chemotherapy or radiation therapy rather than instead of them. Because of that, the most useful approach is to keep your primary oncologist informed and to ask each doctor to speak to the parts of your care they know best.

Your home oncologist knows your diagnosis, stage, treatment history and monitoring plan. The Osaka clinic knows how its cell therapy process works, what its facility can provide, and what it needs from you. Neither can fully answer the other’s questions, so your role is to carry accurate information between them.

Why coordination matters for international and long-distance patients

When treatment is split across places, small gaps can become real problems. A medication change at home may not reach the clinic. A scan result may be interpreted without its context. A planned chemotherapy cycle may be scheduled without anyone checking whether the dates overlap with a cell collection or infusion visit.

For international patients there are additional layers: language, different record formats, different drug names, and the logistics of travelling to Osaka and returning home. Planning ahead reduces the chance that an important detail is lost between two health systems. It also helps you avoid making decisions under time pressure during a short stay in Japan.

What to gather before you ask for a consultation

A consultation is more productive when the doctor can see your history. Although the exact documents requested can differ, the following are commonly useful to prepare. Ask the clinic which of them it needs, and in what language or format.

• A summary letter from your oncologist covering diagnosis, stage and treatment history.
• Recent blood test results and imaging reports, ideally with dates.
• A current list of medications, including supplements and any immune-related drugs.
• Details of your current or planned standard treatment schedule.
• Any history of allergies, infections or other conditions that your doctors consider important.

If your records are in a language other than English or Japanese, ask whether a translation is needed. Providing records in advance, where the clinic offers that option, may help the doctor give more specific guidance at the first consultation. Keep copies of everything you send.

Questions to bring to your home oncologist

It can feel awkward to tell your oncologist that you are exploring an additional therapy. Most doctors prefer to hear about it early, because they need to know everything that might affect your treatment. You might frame the conversation as a request for information rather than a request for approval.

• Are there points in my treatment plan when a blood collection or an infusion visit would be difficult to schedule?
• Are there any medications or procedures that you would want to discuss before I add another therapy?
• What follow-up tests will you continue to run, and can you share the results with another clinic if I ask?
• If I experience a fever, fatigue or another symptom after returning home, who should I contact first?

Your oncologist may have reservations, and those are worth hearing. Cell therapies of this kind are still being studied, and published evidence in this field varies by cancer type, cell source and study design. A careful doctor will often point out that the evidence is limited or uneven. Treat that honesty as useful information rather than as opposition.

Questions to bring to the Osaka clinic

At the consultation, the clinic doctor can explain how NK cell therapy would fit your situation. The clinic describes safety management under Japan’s Act on the Safety of Regenerative Medicine, with treatment provided under a plan submitted to and accepted by the authorities. It is reasonable to ask the clinic to explain that framework in plain language and to tell you where the cells are processed.

• Is NK cell therapy appropriate for my diagnosis and stage, and what are its limitations in my case?
• What are the possible side effects, such as temporary fever or fatigue, and how are they handled?
• How many visits are involved, how long does each stage take, and how long would I need to stay in Osaka?
• What is the full cost, what is included, and what is not included?
• Will the clinic be willing to send a report to my oncologist, and in what form?
• What support is available in English, and is there an information page or interpreter service for international patients?

Because the therapy is outside national insurance coverage in Japan, costs are paid by the patient. Ask for the fee structure in writing before you decide, and confirm what happens if your plans change or if treatment cannot proceed for medical reasons.

Keeping information flowing after you return home

Coordination does not end when you leave Osaka. Ask both sides how follow-up will work. For example, you may want a written summary of what was done, the dates of any infusions, and any symptoms observed afterwards. Your home oncologist can then place those details in your overall record.

It also helps to agree in advance on what to do if something unexpected happens. Know which doctor to call, which hospital to visit in an emergency, and what information to bring. Do not delay urgent care because you are unsure which team should respond; seek medical attention locally first and inform the others afterwards.

Summary: a practical checklist before you decide

Bringing NK cell therapy into a treatment plan that already involves another oncologist is largely a matter of communication. Share your records, tell your home doctor what you are considering, and ask the Osaka clinic to explain its process, costs, risks and limits. The decision is yours, and it should be made with the advice of the doctors who are responsible for your care.

If you would like to learn more, Grand Green Osaka Umekita Clinic in Osaka offers consultations about NK cell therapy and provides an information page for international patients. Whether the therapy is suitable for you can only be judged by a doctor after a consultation, and it is always considered in the context of your standard cancer treatment rather than in place of it.

• Gather your recordsSummary letter and test results
• Keep home doctor informedAlongside standard care
• Ask the Osaka clinicProcess, costs, risks, limits
• Share follow-upKeep both teams updated

This figure is a conceptual diagram that summarizes the article

References

• PubMed: Natural killer cell-based immunotherapy for cancer. (2025)
• PubMed: CAR-NK cells: A promising cellular immunotherapy for cancer. (2020)
• PubMed: Emerging trends in clinical allogeneic CAR cell therapy. (2025)
• PubMed: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. (2023)
• PubMed: Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. (2020)
• PMC: Advances in natural killer cell immunotherapy for hematologic malignancies. (2026)
• PMC: Natural killer cell-based immunotherapy for cancer. (2025)
• PMC: Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. (2019)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.